Since the initial report of robot-assisted laparoscopic prostatectomy (RALP) in 2001, the technique has gained rapid acceptance and utilization. When compared with more traditional forms of surgical intervention, there is still much debate with respect to cost, and impact on potency and continence. Less often is the focus on oncologic outcomes. Pelvic lymph node dissection (PLND) at the time of prostatectomy is an important part of the surgical intervention for prostate cancer and is currently underreported during robotic procedures. Herein, we review the current controversies on the value and extent of PLND and the status of emerging data regarding robot-assisted PLND.
Introduction
Radical prostatectomy has undergone an evolution in technique over many decades with older procedures being largely replaced by newer ones due to perceived superiority of oncologic outcomes or diminution of operative morbidity. [1] [2] [3] In the United States, da Vinci robot-assisted laparoscopic prostatectomy (RALP) has gained rapid popularity because of the facility with which it allows laparoscopic skills to be transferred to even non-laparoscopically trained surgeons. 4 Thus, the benefits of laparoscopy, enhanced optical magnification, decreased blood loss, and minimal incisions can be obtained without prolonged learning curves. Any time a new technique is introduced, it must be compared with current methods to ascertain at least equivalent outcomes, in addition to assessment of benefits, and limitations. To this end, there have been recent publications from the centers of excellence attempting to compare RALP to radical retropubic and pure laparoscopic techniques. 5, 6 However, there has been a paucity of literature addressing pelvic lymph node dissection (PLND) at the time of RALP. This is not the case with all urologic robot-assisted procedures; recent literature on robot-assisted radical cystectomy has specifically focused on feasibility and adequacy of robot-assisted PLND. 7 Thus, the lack of literature on robot-assisted PLND at RALP may reflect that PLND at the time of prostatectomy performed through open technique (or otherwise) is a controversial topic. Important questions remain regarding patient selection, potential benefit and anatomic extent of the dissection, nodal yield, and complication rates. We will review these controversies and the state of the literature regarding RALP PLND in this context.
Ongoing controversies in PLND
In the United States, prostate cancer is the most commonly diagnosed noncutaneous cancer and the second-leading cause of cancer death among men. In 2008, 186 320 men were diagnosed with, and 28 660 men died of, prostate cancer in the United States. 8 The advent of prostate-specific antigen (PSA) screening has led to a profound stage migration such that men diagnosed in the PSA era are younger and have lower clinical and pathologic stage and lower mortality rates, and when treated they have improved margin-free status and biochemical progression-free survival and decreased extracapsular extension and lymph node metastasis. [9] [10] [11] [12] PLND at the time of radical prostatectomy unquestionably provides staging information that may help to more accurately define the extent of the disease. Although magnetic resonance lymphangiography and radioisotope-guided sentinel lymph node detection are less invasive measures that hold promise, the only reliable method for determining lymph node invasion (LNI) is through PLND. 13, 14 Staging information obtained through PLND may help to determine the need for additional therapies. Messing et al., 15, 16 in a multiinstitutional randomized trial of 98 men with lymph node-positive prostate cancer, demonstrated that patients receiving immediate androgen deprivation therapy (ADT) had significant improved overall survival, prostate-cancer specific survival, and progression-free survival compared with patients who received ADT at the time of symptomatic recurrence or detection of distant metastases. More recently, a retrospective study in node-positive prostate cancer patients demonstrated that the delivery of adjuvant radiotherapy and ADT was associated with a higher cancer-specific survival (CSS) and biochemical recurrence (BCR)-free survival compared with patients receiving ADT alone. 17 Emerging data suggest that, in addition to staging information, PLND may provide therapeutic benefit. In their cohort of 235 patients with lymph node-positive disease after PLND, Daneshmand et 22 is that routine histopathologic evaluation underdetected the true incidence of nodal metastases. To test this hypothesis they performed immunohistochemical evaluation on LN from 180 patients with T3N0 PCa. Occult lymph node positivity was found in 13.3% of these patients, confirming their hypothesis. Thus, PLND may remove micrometastatic disease that is currently underdetected.
Patient selection
As with any intervention, the selection criteria for PLND should be based on risk versus benefit. Although there is a contested therapeutic advantage to PLND, 23 there is a consensus belief that PLND provides improved staging information that may help guide individualized treatment. This information comes with the cost of a longer surgery and an increased likelihood of complications. 24 The reduction in rates of lymph node positivity during PLND as a result of PSA screening that induced stage migration has led to a change in practice patterns, with fewer surgeons performing LND at the time of prostatectomy and fewer nodes obtained when PLND is performed. 25, 26 Performance of PLND carries a low risk of direct complication but may also be associated with a low-benefit yield.
Therefore, in which patients may PLND be omitted with no impact on oncologic outcomes? Weight et al.
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compared long-term biochemical relapse-free survival rates from a contemporary series of low-risk patients with and without PLND and found that forgoing PLND in patients with favorable tumor characteristics (Gleason score 6 or less, PSA level o10 ng/ml, and clinical stage T1 or T2a) had no impact on biochemical-free relapse recurrence, with 10 years of follow-up. 27 Similarly, in contemporary series of low-risk patients undergoing extended PLND, the probability of detecting positive lymph nodes was o3%. Even strong PLND advocates concede that in these select patients it may be reasonable to forgo PLND, bearing the caveat that many of these patients are understaged preoperatively. 28, 29 The 'Partin tables' were the initial tool constructed to determine the probability of LNI before surgical intervention based on preoperative variables. 30 A common critique of the Partin table prediction of lymph node positivity is that the PLND performed by the Hopkins group would be considered 'standard' or involved only the external iliac and obturator lymph nodes, thus potentially underestimating true lymph node positivity. Since then, many similarly constructed nomograms have been developed to preoperatively risk stratify patients to determine who may safely forgo PLND. The National Comprehensive Cancer Network (NCCN) guidelines state that a PLND may be omitted in patients with a o7% predicted probability of nodal metastasis by (Partin) nomograms, recognizing that this practice will miss some patients with positive lymph nodes. 31 
Anatomic extent of lymph node dissection
Lymphatic drainage of the prostate has been defined anatomically using lymphangiographic studies. The prostate gland drains into the periprostatic subcapsular network and then to the lymph nodes laterally to the hypogastric LN, inferiorly to the pudental and then to the obdurator LN (secondarily), superiorly from the top to the prostate over the bladder to the external iliac lymph nodes just below the bifurcation of the iliac artery, and posteriorly to the presacral lymph nodes. 32 Although multiple templates are described, none of the current PLND templates include all of these areas. 23 Nomenclature such as limited, standard, or extended PLND can create confusion when proper anatomic descriptions are not provided. Templates for PLND may include obturator fossa lymph nodes only; obturator and external iliac lymph nodes; and obturator, external, internal, and common iliac lymph nodes. Some advocate extending the dissection up to the ureteric crossing or beyond. 18 Larger templates have the advantage of including more of the potential landing sites for the metastatic disease at the cost of additional time to perform the procedure and increased morbidity. 24 Heidenreich et al. performed an extended template PLND (ePLND) on 103 consecutive patients and compared this with 100 patients who underwent standard PLND. In the ePLND group, nine lymph node packets were removed in each patient, including bilateral external iliac, internal iliac, obturator, common iliac, and presacral nodes, whereas in the standard PLND group the template was limited to the external and obturator LN packets bilaterally. The anatomic boundaries of the ePLND were the aortic bifurcation cranially, the circumflex artery and coopers ligament caudally, the external iliac vein laterally, and the ureter medially. In these groups with similar preoperative characteristics, the incidence of LNI in the ePLND (26%) was more than double the incidence in the standard PLND group (12%, Po0.03).
28 LNI was found outside of the standard boundaries for PLND 42% of the time. Interestingly, in patients with low-risk prostate cancer, defined by the authors as a PSA o10.6 ng/ml and Gleason score 6 or less, the prevalence of LNI was o2.5%, suggesting that PLND-extended or otherwise-may be omitted on these patients. Indeed, the finding that ePLND results in removal of more LN resulting in greater detection of LNI has been confirmed by other European groups. 33, 34 Because of the increased penetrance of PSA screening in the United States, American cohorts may be at lower risk of LNI than European cohorts, and these findings may not be applicable. 35 The average PSA of 103 patients who underwent ePLND in Heidenreich's series was 15.9 ng/ml and included patients with PSA values as high as 129 ng/ml, which may be higher than many contemporary American cohorts. 28 Clark et al. 36 performed the only trial to randomize patients ePLND (2 cm above the bifurcation of the common iliac to the node of cloquet, and genitofemoral nerve to the bladder side wall, including the internal iliac and presacral LN) on one side, and limited PLND (lPLND) (bifurcation of the common iliac to the node of cloquet, external iliac to the obturator nerve) on the contralateral side in 123 American patients undergoing radical prostatectomy. LNI was found on the side of the ePLND in 4 patients (3.2%), and on the lPLND in 3 patients (2.4%), and on both sides in 1 patient. A trend toward increased complications attributable to lymphadenectomy was noted on the side with ePLND. Thus, the potential benefit of ePLND remains controversial.
Nodal yield
Increased lymph node dissections result in higher nodal counts; however, controversy remains regarding the number of nodes needed to achieve optimal cancer staging. Weingartner et al. 37 performed anatomic autopsy PLND and determined that although there was great interindividual variability, 20 lymph nodes were needed for a 'sufficient' PLND. Briganti et al. examined the results from 858 patients who underwent radical prostatectomy with PLND and utilized receiver operator characteristic curve coordinates to determine the probability of finding LNI based on the number of LN removed and examined. They noted that the probability of detecting LNI was o10% when fewer than 10 nodes were examined and 90% when 28 nodes were removed. 38 However, they also noted that nodal count was dependent on pathologic assessment and method of nodal retrieval and concluded that PLND should be delineated by extent of anatomic distribution rather than nodal number. 39 
Complications of PLND
The most common complications related to PLND include lymph edema and lymphocele due to disruption of lymphatic drainage. Vascular injury, hemorrhage, neural or ureteral injury may occur very rarely during PLND. 24 Venous thrombotic events such as deep venous thromboses and pulmonary emboli are theoretical risks associated with PLND; however, some authors have found equal rates of these events in patients who undergo prostatectomy with or without PLND. 40 The rates of all of these complications are generally low in both lPLND and in ePLND (2.6%) but may be as high as 19.8% even in contemporary series. 33, 41 Factors that may influence these rates include anatomic boundaries of PLND, number of nodes removed, operating surgeon, possible lymphatic obstruction with tumor, heparin administration, and transperitoneal or minimally invasive technique. 24, [40] [41] [42] Musch et al. demonstrated a significantly higher rate of complications in patients undergoing ePLND compared with lPLND. In their study of 1380 patients undergoing PLND at the time of radical retropubic prostatectomy, ePLND was associated with a threefold increase in lymphocele formation and was an independent risk factor for reintervention. 24 Factors that may mitigate the risk of lymphocele, even with ePLND, may include meticulous ligation of the lymphatic drainage as it enters the pelvis, administration of subcutaneous heparin only to the upper extremity, and preserving the fibro-fatty tissue overlying the external iliac artery that contains lymphatics draining the lower extremity. 42, 43 PLND and robot-assisted laparoscopicic radical prostatectomy
Introduction of robotics
Robot-assisted radical prostatectomy (RALP) performed with the assistance of the da Vinci robotic surgical system (Intuitive Surgical, Sunnyvale, CA, USA) was first reported by Binder and Kramer in 2001. 44 The authors successfully completed nine robotic prostatectomies with a mean operative time of 9 h. Bilateral PLND and frozen section analysis were performed in each of these patients before prostatectomy. The nodal yield revealed a median (range) of 7 (4-12) total lymph nodes, and 1 patient was found to have nodal micrometastases on final examination. Since this initial report RALP has gained rapid acceptance and popularity. 45 In 2003, Menon et al. reported results on their series of 4250 RALPs. Before prostatectomy, PLND was performed on patients with PSA score 410 ng/ml, Gleason sum 46, or 450% of the biopsy cores positive for cancer. Forty percentage of the patients underwent PLND, which added 30 min of operating time on average; however, the anatomic boundaries were not defined and the nodal yield was not described. 46 The four-arm da Vinci S model technique for performing prostatectomy was described by Esposito et al. 47 in 2004, in which 154 consecutive patients underwent extraperitoneal RALP; however, no mention was made of lymph node dissection. In 2006, Joseph et al. reported their series of 325 extraperitoneal RALPs. Ninety-two of these patients had PSA 410 and Gleason sum 47 and underwent PLND after prostatectomy but before vesicourethral anastomosis. Nodal yield was not reported but two patients were found to have metastatic disease to their lymph nodes. 48 Rozet et al. 6 compared 133 patients who underwent RALP with 133 matched-paired patients who underwent pure laparoscopic prostatectomy. Two patients who underwent RALP received a PLND, whereas three in the pure laparoscopic group underwent PLND. No data were reported on LNI, anatomic limits of dissection, or complications related to the dissection.
Large series
The rapid increase in adoption of RALP has lead several leading groups to report their experience and outcomes using this technique. Often these reports focus on oncologic outcomes or comparison to a more traditional Robot-assisted lymphadenectomy JL Silberstein et al technique, but some of the largest series have a paucity of data on PLND. Prasad et al. 49 looked at a random 5% sampling of Medicare beneficiaries from 2003 to 2005 and noted that patients who underwent open radical prostatectomy were four times (83 versus 17%, Po0.001) more likely to undergo PLND than patients who underwent any minimally invasive technique, such as laparoscopic or robot-assisted laparoscopic prostatectomy. This report suggests a potential underuse of PLND in minimally invasive approaches that may influence the accuracy of staging and delivery of appropriate adjuvant therapy (Table 1) .
Menon et al. reported their results on 1100 RALPs that included bilateral PLND in patients with Gleason score 7-9, with an average time of 18 min to perform the LND. However, nodal yield, which may serve as a surrogate for adequacy of dissection, was not reported. 50 An updated report from the same group's experience in 2007, which comprised 2766 patients, cited a total of 20 positive nodes. However, total number of patients undergoing PLND, anatomic extent, and nodal yield were not reported. 51 Similarly, when Smith et al.
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compared a cohort of 1238 men undergoing RALP to 509 undergoing radical retropubic prostatectomy, no data on PLND technique or outcomes were included in the analysis. Patel et al. reported on 1500 RALPs. Two patients developed postoperative lymphocele; no description, however, was given of PLND selection criteria, boundaries, number of patients who underwent PLND, or nodal yield. 52 Link et al. 53 reported on 1847 consecutive patients who underwent RALP; 1027 (55.6%) of whom also underwent concurrent PLND, with 15 (1.5%) demonstrating LNI; patient selection criteria, anatomic extent of dissection, and nodal yield were not reported.
High-risk and extended template dissections
PLND provides important staging information, especially in high-risk patients. Additionally, there is a strong trend in the literature toward more extensive lymph node dissections in patients with intermediate and highrisk prostate cancer; in fact, the NCCN guidelines recommend that when PLND is performed it should be an ePLND. Some recent investigators have outlined the feasibility of robot-assisted PLND in high-risk patients as well as robot-assisted ePLND. Seventy of these patients were considered to be at high risk based on a preoperative biopsy Gleason sum between 8 and 10 and all underwent PLND before prostatectomy. Frozen section analysis of lymph node packet performed before prostatectomy revealed metastatic disease in four patients and the investigators opted to terminate these procedures; however, anatomic extent of the LND, total number of nodes removed, and PLNDrelated complications were not described. 54 A recent report by Feike et al. reported outcomes of 99 extended lymph node dissections in patients with either PSA X10 ng/ml, preoperative Gleason sum of X7, or clinical T3 tumor. Their dissection template included the external iliac, obturator, and internal iliac packets, with a median lymph node yield of 19 (mean 19.4; range 8-53) and a median time for dissection completion of 51 min. Positive LN were found in 16% of these patients, and 25% of these were detected around the internal iliac artery. Complications attributed to PLND occurred in 7% of patients (two lower extremity lymph edema, four lymphoceles, and one lympho-cutaneous fistula to a port site that closed spontaneously). 55 The authors demonstrated the feasibility of extended template dissection with a complication rate comparable to that of open ePLND. Although significantly prolonging operative time, ePLND may be performed safely in the setting of RALP with minimal but not negligible patient morbidity. Adoption of ePLND during RALP seems to still be limited even in centers of excellence judging by the current paucity of literature.
Conclusion
The literature clearly shows that the lymphatic drainage of the prostate is not limited to the obturator and external iliac lymph nodes, and thus a PLND limited to these regions does not address all the potential landing sites. An ePLND, especially when including the internal iliac lymph nodes, more accurately reflects the true lymphatic drainage of the prostate, increases nodal yield at the time of PLND, and increases the ability to detect LNI. It seems safe to exclude PLND in patients undergoing any radical prostatectomy for low-risk prostate cancer. Controversy continues concerning the appropriate prostate cancer risk threshold to routinely perform PLND. Patients with high-risk prostate cancer should routinely have ePLND performed at the time of radical prostatectomy, regardless of the technique used. Surgeons performing RALP should strictly adhere to their PLND selection criteria and the extent of dissection that they would have performed as an open procedure. Detailed PLND information, including boundaries of dissection, nodal yield, and results should be mandatory in future robot-assisted prostatectomy publications addressing oncologic outcomes.
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